2015
Human Immunodeficiency Virus and Heart Failure in Low- and Middle-Income Countries
Bloomfield GS, Alenezi F, Barasa FA, Lumsden R, Mayosi BM, Velazquez EJ. Human Immunodeficiency Virus and Heart Failure in Low- and Middle-Income Countries. JACC Heart Failure 2015, 3: 579-590. PMID: 26251085, PMCID: PMC4530470, DOI: 10.1016/j.jchf.2015.05.003.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusHeart failureMiddle-income countriesImmunodeficiency virusChronic diseasesBurden of HIVTraditional cardiovascular risk factorsCommon cardiac diagnosesCardiovascular risk factorsLarge observational studiesLife expectancySuccessful combination therapyCare of peopleAntiretroviral therapyClinical characteristicsTreatment patternsSociety guidelinesCombination therapyRisk factorsClinical studiesObservational studyDiagnostic criteriaCardiac diagnosisHigh mortalityCardiac glycosides
2008
Improvements in Signs and Symptoms During Hospitalization for Acute Heart Failure Follow Different Patterns and Depend on the Measurement Scales Used: An International, Prospective Registry to Evaluate the Evolution of Measures of Disease Severity in Acute Heart Failure (MEASURE-AHF)
Allen LA, Metra M, Milo-Cotter O, Filippatos G, Reisin LH, Bensimhon DR, Gronda EG, Colombo P, Felker GM, Dei Cas L, Kremastinos DT, O'connor CM, Cotter G, Davison BA, Dittrich HC, Velazquez EJ. Improvements in Signs and Symptoms During Hospitalization for Acute Heart Failure Follow Different Patterns and Depend on the Measurement Scales Used: An International, Prospective Registry to Evaluate the Evolution of Measures of Disease Severity in Acute Heart Failure (MEASURE-AHF). Journal Of Cardiac Failure 2008, 14: 777-784. PMID: 18995183, PMCID: PMC3961584, DOI: 10.1016/j.cardfail.2008.07.188.Peer-Reviewed Original ResearchConceptsAcute heart failureHeart failurePatient-reported dyspneaProspective international cohortSymptoms of dyspneaPatient-reported symptomsVisual analog scaleMultiple clinical measuresAHF episodeAHF therapiesProspective registryEjection fractionPhysician assessmentAnalog scaleMean ageVAS measuresInternational cohortClinical measuresDyspneaPhysical signsDischarge decisionsDisease severitySymptomsDifferent patternsHospitalization
2006
Comparison of Regional Versus Global Assessment of Left Ventricular Function in Patients with Left Ventricular Dysfunction, Heart Failure, or Both After Myocardial Infarction: The Valsartan in Acute Myocardial Infarction Echocardiographic Study
Thune JJ, Køber L, Pfeffer MA, Skali H, Anavekar NS, Bourgoun M, Ghali JK, Arnold JM, Velazquez EJ, Solomon SD. Comparison of Regional Versus Global Assessment of Left Ventricular Function in Patients with Left Ventricular Dysfunction, Heart Failure, or Both After Myocardial Infarction: The Valsartan in Acute Myocardial Infarction Echocardiographic Study. Journal Of The American Society Of Echocardiography 2006, 19: 1462-1465. PMID: 17138030, DOI: 10.1016/j.echo.2006.05.028.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntihypertensive AgentsComorbidityEchocardiographyFemaleHeart FailureHumansInternationalityMaleMiddle AgedMyocardial InfarctionPrevalencePrognosisReproducibility of ResultsRisk AssessmentRisk FactorsSensitivity and SpecificityStroke VolumeTetrazolesValineValsartanVentricular Dysfunction, LeftConceptsWall motion indexMyocardial infarctionHeart failureLV dysfunctionEjection fractionIndependent predictorsGlobal assessmentLeft ventricular dysfunctionLV systolic functionVentricular ejection fractionAdditional prognostic informationLeft ventricular functionAcute myocardial infarctionBiplane Simpson's ruleWall motion assessmentVentricular dysfunctionSystolic functionEchocardiographic studyVentricular functionMultivariable analysisPrognostic valueAdverse outcomesPrognostic informationLVEFRegional dysfunctionGeographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
Reed SD, McMurray JJ, Velazquez EJ, Schulman KA, Califf RM, Kober L, Maggioni AP, Van de Werf F, White HD, Diaz R, Mareev V, Murin J, Committees and Investigators F. Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. American Heart Journal 2006, 152: 500-508. PMID: 16923421, DOI: 10.1016/j.ahj.2006.02.032.Peer-Reviewed Original ResearchConceptsHigh-risk patientsAcute myocardial infarctionMyocardial infarctionReperfusion therapyBaseline characteristicsVALIANT trialLeft ventricular systolic dysfunctionTime of MIAcute Myocardial Infarction trialSafety of captoprilMyocardial Infarction trialPatient baseline characteristicsUse of aspirinVentricular systolic dysfunctionProportion of patientsCare of patientsEvidence-based therapiesMultivariable regression modelsSystolic dysfunctionHeart failureTrial populationKey treatmentPatientsInternational trialInternational guidelines